Will Star Health and HDFC ERGO cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Beovu is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by CDSCO?

The CDSCO named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; CDSCO review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Indian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The State Medical Council and the CDSCO Zonal Office verifies the active license; the CDSCO application records both the prescribing physician and the dispensing facility.

Can I receive Beovu at home?

The dispensing facility must be Indian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 1,900 to 2,200 per dose. Delivered quote within 24h.Get my quote

Beovu access in India: the CDSCO named-patient pathway

How patients in the Republic of India legally obtain Beovu (brolucizumab-dbll) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in India access Beovu (brolucizumab-dbll) for neovascular (wet) age-related macular degeneration and diabetic macular edema through the CDSCO named-patient pathway, a Central Drugs Standard Control Organisation-administered mechanism that allows an Indian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in INR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Beovu reaches patients in India

Beovu (brolucizumab-dbll, a humanised single-chain antibody fragment binding VEGF-A from Novartis, FDA-approved October 2019 for neovascular wet age-related macular degeneration and subsequently for diabetic macular oedema, label resource at accessdata.fda.gov) has had a complex post-marketing safety profile internationally, with the FDA label carrying a warning for retinal vasculitis and retinal vascular occlusion. The Central Drugs Standard Control Organization SUGAM approved-product search at cdscoonline.gov.in should be checked for current registered status at the snapshot date; where Beovu is not stocked at the specific presentation or strength a treating retinal specialist has prescribed, patients access the medicine under the Permission to Import Small Quantities of New Drug for Personal Use, the statutory Form 12-B Permit applied for via Form 12-A under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945 read with the New Drugs and Clinical Trials Rules 2019, pathway page at cdsco.gov.in/Drugs-for-Personal-Use. Applications are filed online through the SUGAM portal at cdscoonline.gov.in/CDSCO/Drugs_Personal. CDSCO public materials describe Form 12-B issuance within one to two working days when documentation is complete. Where the dispensing hospital is the importer-of-record for an admitted named patient, the parallel Import Licence for Personal Use in CT Form-16 under the New Drugs and Clinical Trials Rules 2019 applies, rules text at cdsco.gov.in/Acts-and-rules/New-Drugs. The prescribing retinal specialist's National Medical Commission registration number, the case summary, and a pro-forma invoice support the file. Form 12-B is single-consignment per shipment cycle.

Where Beovu is dispensed in India

Beovu is administered as a 6 mg intravitreal injection in a sterile vitreoretinal clinic setting following a loading phase then maintenance every 8 to 12 weeks. Indian dispensing routes through vitreoretinal subspecialty programmes at dedicated eye institutes and tertiary ophthalmology services. L V Prasad Eye Institute at Hyderabad and Bhubaneswar runs one of India's most-cited vitreoretinal services, at lvpei.org. Sankara Nethralaya Chennai operates a national-referral retina service, at sankaranethralaya.org. Narayana Nethralaya Bangalore is a tertiary retina referral node, at narayananethralaya.org. Aravind Eye Care System Madurai, Coimbatore, Tirunelveli, Pondicherry, and Theni hosts a large public-volume retina service, at aravind.org. Among tertiary academic centres, the All India Institute of Medical Sciences New Delhi Dr R P Centre for Ophthalmic Sciences, at aiims.edu, and the Postgraduate Institute of Medical Education and Research Chandigarh Advanced Eye Centre operate vitreoretinal services. Among private tertiary nodes, Apollo Hospitals Chennai, Delhi, and Hyderabad, Kokilaben Dhirubhai Ambani Hospital Mumbai, and Fortis Memorial Research Institute Gurugram routinely handle intravitreal biologic imports. The dispensing pharmacy releases for same-session injection rather than outpatient home storage.

What Beovu costs in India

The US wholesale acquisition cost for Beovu is reported in the range of approximately USD 1,702 to USD 1,998 per 6 mg single-dose vial or prefilled syringe, sourced from Novartis disclosures and Drugs@FDA at accessdata.fda.gov. Annualised cost depends on the treating retinal specialist's loading and maintenance schedule per the FDA-approved label for wet AMD and diabetic macular oedema; a maintenance interval of every 8 to 12 weeks yields roughly 4 to 6 doses per year after the loading phase. No public local-currency benchmark for Beovu specifically in INR is observed on the National Pharmaceutical Pricing Authority ceiling-price database at nppaindia.nic.in as of 2026-06-01 for the named-patient import use case; do not estimate. Price snapshot: 2026-06-01. Cost layers stacked on the drug cost include international validated 2 to 8 degree Celsius cold-chain freight, CDSCO permit and customs handling (nominal relative to drug cost), the vitreoretinal facility's injection-procedure charge, the OCT and FAF baseline and follow-up imaging fees, and the Reserve Meds concierge fee itemised separately on every firm quote. Goods and Services Tax on life-saving medicines sits at 5 percent.

Funding and access barriers for Beovu in India

Funding for anti-VEGF intravitreal therapy in India varies sharply by sector. The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana hospitalisation cover at INR 5 lakh per family per year covers selected ophthalmology procedures for eligible beneficiaries but specialty intravitreal biologics are policy-package specific. Public-sector tertiary eye institutes operate sliding-scale charges; AIIMS Delhi and the regional government medical college network typically subsidise intravitreal injections at the procedure level while patients self-pay for the drug. Indian private health insurers including Star Health, Niva Bupa, HDFC ERGO Health, Care Health, ManipalCigna, ICICI Lombard, and Bajaj Allianz cover intravitreal anti-VEGF therapy variably; many plans pay the procedure but cap the drug at the locally registered biosimilar or branded alternative. Coverage of an unregistered named-patient import of Beovu specifically is not the norm and requires case-by-case adjudication, often citing the FDA-labelled indication and the retinal specialist's clinical rationale relative to locally available agents. The National Programme for Control of Blindness at npcbvi.mohfw.gov.in operates a national blindness-prevention infrastructure but does not generally fund individual anti-VEGF agents at originator-brand pricing. Family self-pay through diaspora remittance is a common pattern. The post-marketing retinal vasculitis safety signal has shifted some prescribers toward aflibercept (Eylea), ranibizumab (Lucentis or its biosimilars), or faricimab (Vabysmo) as first-line; named-patient Beovu requests now sit primarily where the retinal specialist has weighed the safety signal against the patient's clinical profile and the longer maintenance interval.

Recent regulatory and access news for Beovu

The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a brolucizumab-specific Indian notification over the last 12 months as of 2026-06-01. The US FDA prescribing information for Beovu retains the warning regarding retinal vasculitis and retinal vascular occlusion, with the most current label at accessdata.fda.gov. The European Medicines Agency human medicines portal at ema.europa.eu continues to publish periodic safety updates for the agent. The All India Ophthalmological Society and the Vitreoretinal Society of India have continued retinal vasculitis surveillance reporting through 2025 and 2026 with no India-specific regulatory restriction beyond the labelled warnings observed at the snapshot date.

Where Reserve Meds fits in Beovu cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace CDSCO, and we do not replace your dispensing pharmacy. For Beovu specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into India, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Beovu case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the CDSCO application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Beovu is administered by intravitreal injection in a sterile clinic setting; named-patient files in India document the baseline OCT and FAF imaging, the FDA-labelled dosing schedule for the specific indication (wet AMD, DME, RVO, or DR), and the retinal specialist's intravitreal injection volume. Cold-chain (2 to 8 degrees Celsius) handling is required through the dispensing pharmacy with continuous temperature logging; the dispensing pharmacy releases the medicine for same-session injection at the clinic rather than for outpatient home storage.

Next step

If your Indian physician has prescribed Beovu and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Beovu case Or message us on WhatsApp